Cebert Pharmaceuticals, Inc.
Monday, October 13, 2003

CEBERT PARTNERS WITH CARDINAL HEALTH TO DEVELOP ANXIETY PRODUCT

CONTACT: Jim Watkins

BIRMINGHAM, AL (October 13, 2003) -- Cebert Pharmaceuticals, Inc. announces it has entered into an agreement with Cardinal Heath to develop a new, proprietary product for the treatment of Anxiety and Panic Disorder.

This product will take advantage of the patented Zydis technology owned by Cardinal. Cardinal’s Zydis technology is a freeze-dried orally dispersible tablet. It has many advantages over existing technologies, such as a more rapid dissolution and less grainy aftertaste.

Cebert CEO, Royce Watkins says, ‘We are excited about partnering with a company such as Cardinal Health. The combination of cutting-edge technology and their position within the healthcare industry make them a most desirable partner.’

Headquartered in Dublin, Ohio, Cardinal Health, Inc. is an $80 billion, global company serving the health-care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients. With a focus on making supply chains more efficient, reducing hospital-acquired infections and breaking the cycle of harmful medication errors, Cardinal Health develops market-leading technologies. The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide. Ranked No. 19 on the Fortune 500 and No. 1 in its sector on Fortune's ranking of Most Admired firms, Cardinal Health employs more than 40,000 people on five continents.

Cebert Pharmaceuticals, Inc. is a Birmingham, Alabama based pharmaceutical company which concentrates on the acquisition and/or licensing of existing proprietary products, along with the development of new, innovative products for a defined niche.